{"id":"W3111254209","doi":"10.3747/co.27.7159","title":"Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Lenvatinib; Sorafenib; Medicine; Hepatocellular carcinoma; Atezolizumab; Regorafenib; Oncology; Bevacizumab; Internal medicine; Immunotherapy; Nivolumab; Cancer; Colorectal cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005937206,0.0004674802,0.0009563859,0.001782163,0.0002070833,0.0007968795,0.0005476951,0.0006512115,0.002975816],"category_scores_gemma":[0.0009852673,0.000131514,0.0006374546,0.00153104,0.0002913378,0.001034045,0.0004827262,0.001417224,0.0009817386],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005515277,"about_ca_system_score_gemma":0.0009685881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008334328,"about_ca_topic_score_gemma":0.002481529,"domain_scores_codex":[0.9998215,0.00004520588,0.00003200763,0.00002429936,0.00006018092,0.00001676999],"domain_scores_gemma":[0.999546,0.000257558,0.00006443405,0.000009949516,0.00009575172,0.00002620924],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006495057,0.00003687912,0.0002028509,0.01884944,0.0001352009,0.000148161,0.0000520397,0.0002449256,0.000478027,0.002381191,0.01967528,0.9577311],"study_design_scores_gemma":[0.00002671173,0.0001244576,0.001245769,0.01253602,0.0003105705,0.001861683,0.00009268266,0.0001347729,0.0002458587,0.002543897,0.9808595,0.00001805328],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007541029,0.9989956,0.00004973812,0.0003252024,0.0001281342,0.000001902951,0.000008186127,0.000002947745,0.0004128824],"genre_scores_gemma":[0.0004793718,0.9989793,0.00006459669,0.0001849466,0.0001097802,0.000001978741,0.00001505636,7.810455e-7,0.000164131],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002975816,"threshold_uncertainty_score":0.009955108,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2405468406013818,"score_gpt":0.3780432350626574,"score_spread":0.1374963944612756,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}